Dergiler / Uluslararası Hematoloji-Onkoloji Dergisi / 2020 / Cilt: 30 - Sayı: 4

Breast Cancer Among Patients Below Age 40: Clinicopathological Features and Survival Results

Sayfa
230–237
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

It is suggested to conduct further studies on specific tumor biology to analyze the same group with respect to the characteristics of more aggressive tumors

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Among young women breast cancer exhibits quite a heterogenous, quite agressive and complex biology.
📊
Temel Bulgular & Veri:The purpose of this study is to describe clinicopathological features that affect survival ratio among breast cancer women below age-40. 803 patients having received adjuvant radiotherapy were retrospectively analyzed.
💡
Sonuç & Katkı:It is suggested to conduct further studies on specific tumor biology to analyze the same group with respect to the characteristics of more aggressive tumors
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Among young women breast cancer exhibits quite a heterogenous, quite agressive and complex biology. The purpose of this study is to describe clinicopathological features that affect survival ratio among breast cancer women below age-40. 803 patients having received adjuvant radiotherapy were retrospectively analyzed. Patients were categorized under two groups: age ≤ 40 and age > 40. Treatments and clinicopathological features were analyzed. 19.4% (156) of 803 patients were below age 40. In patient group below age 40, more neoadjuvant chemotherapy (NAC) was administered compared to the patient group above age 40 (p= 0.007) and it was detected that there were higher incidences of stage 3 disease (p= 0.011), more advanced nodal disease (N2-3) (p= 0.046) and more metastasis (p< 0.001). In conducted multivariate analysis for all age groups presence of N2-3 disease (p= 0.011) and in below age-40 group being grad 3 (p= 0.025) was found to affect overall survival (OS) negatively. In disease free survival (DFS)-focused analysis; for all age groups, receiving NAC (p= 0.001), presence of N2-3 disease (p= 0.002) and being below age 40 were found to have a nega-tive effect; in below age-40 group presence of NAC (p= 0.013) and perineural invasion (p= 0.035); in above age-40 group receiving NAC (p= 0.023) and presence of N2-3 disease (p= 0.035) had a negative effect. Being below age 40 is an independent prognostic factor for DFS. It is suggested to conduct further studies on specific tumor biology to analyze the same group with respect to the characteristics of more aggressive tumors

🔖

Bu Makaleye Atıf Yap

YAVUZ, B. B., AKTAN, M., KANYILMAZ, G. (2020). Breast Cancer Among Patients Below Age 40: Clinicopathological Features and Survival Results. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 30 - Sayı: 4, 230–237. https://ajindex.com/articles/322730

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Mustillo A, Ayoub JP, Charpentier D, et al. Prognosis in young women less than 40 years of age with brain metastasis from breast cancer. Curr Oncol 27: 39-45, 2020. 2.Anastasiadi Z, Lianos GD, Ignatiadou E, et al. Breast cancer in young women: an overview. Updates Surg 69: 313-317, 2020. 3.SEER DATA: Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2017,
  2. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975 2017/, based on November 2019 SEER data submission, posted to SEER web site. Access date: April 2020. 4.Plichta J, Thomas SM, Vernon R, et al. Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age. Breast Cancer Res Treat 180: 227-235, 2020. 5.Ribnikar D, Riberio JM, Pinto D, et al. Breast cancer under age 40: a Different approach. Curr Treat Options in Oncol 16: 16, 2015. 6.Limbach KE, Leon E, Pommier RF, Pommier SJ. Compari-sion of breast cancer incidence, clinicopathologic features, and risk factor prevalance in women aged 20-29 at diagnosis to those aged 30-39. Breast J 26: 1069-1070, 2020. 7.Gnerlich JL, Deshpande AD, Jeffe DB, et al. Elevated breast cancer mortality in young women ( 8.Radecka B, Litwiniuk M. Breast cancer in young women. Ginekol Pol 87: 659-663, 2016. 9.Kroman N, Jensen MB, Wohlfahrt J, et al. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 320: 474-478, 2000. 10.Amin MB, Edge S, Greene F, et al (eds). AJCC Cancer Stag-ing Manual.8th edition. Springer, 2017: 589-628. 11.Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statis-tics 2018: GLOBACAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 694-424, 2018. 12.Wong FY, Tham WY, Nei WL, et al. Age exerts a continu-ous effect in the outcomes of Asian breast cancer patients treated with breast-conserving therapy. Cancer Common 38: 39, 2018. 13.Durhan G, Azizova A, Onder O, et al. Imaging findings and clinicopathological correlation of breast cancer in women un-der 40 years old. Eur J Breast Health 15: 147-152, 2019. 14.Love RR, Due NB, Dinh NV, et al. Young age as an adverse prognostic factor in premenopausal women with operabl breast cancer.Clin Breast Cancer 2: 294-298, 2002. 15.Peng R, Wang S, Shi Y, et al. Patients 35 years old or younger with operable breast cancer are more at risk for relapse and survival: A retrospective matched case-control study. Breast 20: 568-573, 2011. 16.Zhao